Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302 Academic Article uri icon


MeSH Major

  • Abiraterone Acetate
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Steroid Synthesis Inhibitors


  • Treatment patterns for advanced prostate cancer have changed substantially in the last few years. This additional analysis provides evidence of clinical benefit for subsequent chemotherapy in men with advanced prostate cancer whose disease progressed after treatment with abiraterone acetate. Older patients were less likely to be treated with subsequent therapy.

publication date

  • January 2016



  • Academic Article



  • eng

PubMed Central ID

  • PMC5609503

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2016.06.033

PubMed ID

  • 27402060

Additional Document Info